# Bright Peak Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bright-peak-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.brightpeaktx.com/
- Total disclosed funding: $232M
- Latest round: Series C (Jun 11, 2024)
- Investors on record: 11

## About

Founded in 2017 by Vijaya R. Pattabiraman (CTO) and Jeffrey Bode and based in Basel, Switzerland, Bright Peak Therapeutics AG operates as a biotechnology company that focuses on the development of synthetic protein therapeutics for healthcare institutes to have a specific immuno-oncology indication, modification, and conjugation. In June 2024, Bright Peak Therapeutics, Inc. raised USD 90 million in Series C funding led by Johnson & Johnson Innovation, including Venrock, KB Investment, and Northleaf Capital Partners, Fidelity Management, RA Capital Management, Qatar Investment Authority, Invus, and Alexandria Venture Investments. As of 2024, the company is led by its CEO, Fredrik Wiklund. The company also has a presence in the US.

The company specializes in developing next-generation precision immunotherapies through advanced protein engineering. The firm utilizes its proprietary chemical protein synthesis platform to create multifunctional immunotherapies for treating cancer and autoimmune diseases. Bright Peak's approach leverages protein design to enhance therapeutic efficacy and specificity. The company's pipeline includes a range of designer immunotherapies that are engineered to offer targeted and effective treatment options.

The organization plans to use the June 2024 funding to enhance its pipeline of next-generation immunotherapies.

## Funding rounds

- Series C, Jun 11, 2024, $90M — Northleaf Capital Partners, Versant Ventures, Venrock, Alexandria Venture Investments, Johnson & Johnson Innovation, Invus [DUP], Fidelity Investments, KB Investment, Qatar Investment Authority, RA Capital Management
- Series B, Jun 10, 2021, $107M — Versant Ventures, Alexandria Venture Investments, Invus [DUP], Qatar Investment Authority, Fidelity Investments, BlackRock, RA Capital Management
- Series A, Jul 28, 2020, $35M — Versant Ventures

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- Invus [DUP] — Series B, Series C
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Northleaf Capital Partners (https://capitalatlas.ai/funds/northleaf-capital-partners) — Series C
- Venrock (https://capitalatlas.ai/funds/venrock) — Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series C